Cooley M&A

FEBRUARY 8, 2018

What’s on tap for 2018 M&A? No longer just “acquihires,” today’s innovation-driven acquisition is focused on talent retention. One familiar technique used by sophisticated tech buyers is a holdback structure that subjects a portion of key employees’ merger consideration to revesting. 280G Gross-Ups in Public Company Sales.

M&A 52

M&A Mergers and Acquisitions Mergers Negotiation 52

Devensoft

JUNE 19, 2023

Mergers and acquisitions (M&A) constitute intricate and frequently risky transactions with significant implications for stakeholders. That’s why companies need to approach M&A deals with a strategic mindset that minimizes risk and maximizes value.

M&A 52

M&A Mergers and Acquisitions Mergers Management 52

Devensoft

AUGUST 22, 2023

Embracing Innovation in M&A Strategies As the M&A landscape evolves, the call for innovation grows louder. Enter freelance modeling—a dynamic concept that adapts M&A to the fast-paced, unpredictable realm of modern business. In the upcoming sections, we explore how freelance modeling reshapes M&A norms.

M&A 52

M&A Business Mergers and Acquisitions Collaboration 52

Cooley M&A

JANUARY 23, 2024

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. billion; Bristol Myer Squibb’s acquisition of RayzeBio for $4.1 billion, and Karina for $14 billion; AstraZeneca’s acquisition of Gracell Biotechnologies for up to $1.2

M&A 52

M&A Mergers and Acquisitions Acquisitions Pharmaceutical 52

Software Equity Group

JUNE 6, 2023

A key indicator is the increasing number of SaaS M&A transactions as companies seek to expand into new markets, consolidate current markets, provide end-to-end solutions, and take advantage of synergies. As a trusted partner in SaaS M&A, we are thrilled to have played a pivotal role in these significant deals.

M&A 52

M&A Mergers and Acquisitions Middle Market Acquisitions 52

The Harvard Law School Forum

JUNE 16, 2023

Posted by Sally Wagner Partin, Sharon Flanagan, and Hannah M. Flanagan are Partners and Hannah M. Related research from the Program on Corporate Governance includes Are M&A Contract Clauses Value Relevant to Target and Bidder Shareholders? Brown is an Associate at Sidley Austin LLP.

M&A 40

M&A Pharmaceutical Acquisitions Valuation 40

Cooley M&A

JANUARY 25, 2023

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 22, 2021

General Trends in Life Sciences M&A. In contrast, aggregate M&A deal value for the life sciences sector was down nearly 50% when compared to 2019, with the first half of 2020 particularly dismal in the wake of market uncertainty caused by the pandemic.

M&A 40

M&A Mergers and Acquisitions Collaboration Mergers 40

InvestmentBank.com

AUGUST 14, 2019

The benefits of VR are not limited to language immersion, architecture, interior design, space expedition, biology, chemistry or pharmaceutical practices. Students (K-12) participating in schools with technological integration efforts achieved an increase of 94 points on average in SAT I performance [1]. billion in 2018 in the U.S.,

Education 52

Education Mergers and Acquisitions Capital Investment 52

M&A Leadership Council

SEPTEMBER 26, 2024

Assessing Your Fit for the Role of Integration Management Office Lead By M&A Leadership Council In M&A, the Integration Management Office (IMO) Lead plays a critical role in ensuring a smooth, efficient integration process. The position requires strategic insight, operational knowledge, and strong leadership.

Mergers and Acquisitions 52

Mergers and Acquisitions M&A Management Mergers 52

Cooley M&A

OCTOBER 24, 2024

While this mantra may help bruised egos on the playground, it’s of no use in M&A disputes. Alexion Pharmaceuticals (Del. This dynamic has increased the number of earnout/milestone disputes and is influencing how earnout provisions are negotiated in acquisition agreements. In both Fortis v. Johnson & Johnson (Del.

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Negotiation Sale 52

M&A Leadership Council

AUGUST 15, 2022

Fundamentals of M&A: An Excerpt from The Art of M&A Book Series. By Alexandra Reed Lajoux, Board of M&A Standards/Founding Principal at CapEx . Few companies divest units immediately following an acquisition (unless they are compelled to do so by antitrust regulators), but many companies divest them eventually.

Mergers and Acquisitions 40

Mergers and Acquisitions IPO M&A Initial Public Offering 40

Cooley M&A

OCTOBER 29, 2018

M&A practitioners have long advised boards of directors that the Delaware courts have never found that the events or circumstances in a particular transaction met the contractual standard of having a material adverse effect (or MAE) as defined in a merger or acquisition agreement. The Merger Agreement.

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Business Pharmaceutical 52

Peak Frameworks

SEPTEMBER 19, 2023

The distinction between them is crucial for understanding a company's obligations, its strategy, and the interplay of interests within its ecosystem. What is a Shareholder? A shareholder is an individual or entity that owns shares or stock in a corporation. Shareholders: are primarily concerned about financial returns.

Corporation 52

Corporation Private Equity Mergers and Acquisitions Corporate Finance 52

Devensoft

AUGUST 24, 2023

By melding the proficiencies, assets, and potentials residing within distinct business sectors or entities under a single organizational umbrella, the practice of mergers and acquisitions unveils dormant possibilities, propels inventive evolution, and champions the delivery of unparalleled outcomes. Get a copy to-go.

Business 52

Business Collaboration Mergers and Acquisitions Management 52

Cooley M&A

APRIL 7, 2017

According to a recent study by SRS of recent private life sciences deals, disputes over earn-outs arose in about one-third (36%) of all milestones that were expected to be hit by September 2016. [1] for a Hematologic Cancer Indication.”

Mergers and Acquisitions 40

Mergers and Acquisitions Negotiation Pharmaceutical IT 40

Cooley M&A

JANUARY 20, 2022

General trends in life sciences M&A. While 2020’s M&A landscape was characterized by whiplash volatility from choppy deal activity in the first half of the year to a surge in volume in the second half, that momentum accelerated in 2021, with no signs of slowing down heading into 2022. With COVID?19 driven assets.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

OfficeHours

JANUARY 26, 2024

Yes and it’s going to be great Yes and it sucks No but I’m optimistic No and I’m not optimistic Login or Subscribe to participate in polls. Some dealmakers claim the impact of elections on mergers and acquisitions is minimal. Have you received word on your bonus yet?

Private Equity 130

Private Equity Equities Mergers and Acquisitions M&A 130

The Deal

NOVEMBER 19, 2023

It’s not uncommon to see a big-ticket M&A deal get stifled after a deal announcement. While the issue has been intensifying over the past decade, in July the Biden administration proposed new merger guidelines to further protect competition. carve-outs or divestitures) before entering a merger agreement.

M&A 59

M&A Mergers Pharmaceutical IT 59

Mergers and Inquisitions

NOVEMBER 1, 2023

PE firms view these companies as especially appealing since low multiples mean they can use higher debt percentages to fund the acquisitions. Fragmented Markets with Many Add-On Acquisition Opportunities – Private equity firms have been snapping up specialist physician practices in the U.S. Why do PE firms operate there?

Private Equity 59

Private Equity Healthcare Equities Middle Market 59

Cooley M&A

JULY 21, 2021

Here is a breakdown of the key aspects of the order that affect tech and life sciences companies, and what to expect around the corner: Expect increased merger scrutiny. The White House called for the antitrust agencies to correct course and “challenge prior bad mergers the past administration did not previously challenge.”.

Mergers and Acquisitions 40

Mergers and Acquisitions Mergers Pharmaceutical M&A 40

MergersCorp M&A International

NOVEMBER 16, 2024

His presidency brought with it a unique set of policies and attitudes that would directly influence the realm of mergers and acquisitions (M&A). This post will delve into how Trump’s administration impacted M&A activities, examining both the opportunities created and the challenges faced during his tenure.

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Acquisitions M&A 52

Cooley M&A

JANUARY 21, 2022

Procedural upheavals have swept the merger review process, erecting new hurdles that merging parties must leap over, from the “temporary” suspension of early termination to the FTC’s issuance of pre-consummation “warning letters.” Increasing procedural hurdles to merger review. Increasing procedural hurdles to merger review.

Mergers and Acquisitions 40

Mergers and Acquisitions Mergers Pharmaceutical IT 40

Cooley M&A

JANUARY 18, 2017

Uncertainty over how vigorous merger enforcement will be in the Trump Administration. The Obama Administration went out with a bang in 2016 on the merger enforcement front in potential reaction to criticism from the left that previous enforcement had been lax. Transition to a Trump Administration is top of the agenda.

Mergers and Acquisitions 40

Mergers and Acquisitions Pharmaceutical Mergers Investment 40

InvestmentBank.com

MAY 18, 2021

The healthcare industry is formed of numerous subsectors including pharmaceutical services, diagnostics, medical technologies, and managed healthcare. Payor services and pharmaceutical services have generated the most return throughout 2016 and in 1Q 2017. The pharmaceutical industry is valued highly given the performance of buyouts.

Healthcare 40

Healthcare M&A Valuation Hospitality 40